NKTR Nektar Therapeutics

17.3
+1.43  (+9%)
Previous Close 15.87
Open 15.83
Price To Book 1.95
Market Cap 3,031,371,665
Shares 175,274,453
Volume 3,214,679
Short Ratio
Av. Daily Volume 4,397,432
Stock charts supplied by TradingView

NewsSee all news

  1. Nektar Therapeutics Announces Initiation of Two Clinical Studies of Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Psoriasis and Atopic Dermatitis

    SAN FRANCISCO, Oct. 7, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced the initiation of two Phase 1b studies of NKTR-358 (LY3471851*), a novel T regulatory (Treg) cell stimulator, one in patients

  2. Nektar Therapeutics Announces Five Abstracts Accepted for Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    SAN FRANCISCO, Oct. 2, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced the acceptance of five clinical and preclinical data abstracts for its immuno-oncology portfolio at the 2019 Society for

  3. Nektar Announces Key Executive Promotions

    SAN FRANCISCO, Oct. 1, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today several promotions on its executive leadership team:  Jonathan Zalevsky, Ph.D. has been promoted to Chief Research &

  4. Las Vegas Sands Set to Join S&P 500; Nektar Therapeutics to Join S&P MidCap 400; The Pennant Group to Join S&P SmallCap 600

    NEW YORK, Sept. 26, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600: Las Vegas Sands Corp. (NYSE:LVS) will replace Nektar

  5. Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Triple-Negative Breast Cancer Patients at the 2019 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

    SAN FRANCISCO, Sept. 26, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today a presentation of new clinical data for bempegaldesleukin (bempeg, NKTR-214) in combination with nivolumab in patients with

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 updated data due at SITC November 9, 2019, 5:15 p.m.
NKTR-214 + OPDIVO (nivolumab) - PIVOT-2
Urothelial carcinoma, Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers
Phase 1/2 commencement of dosing announced September 12, 2017. Initial data presented at ASCO 2018
NKTR-214 + TECENTRIQ + KEYTRUDA (PROPEL)
Solid tumors - cancer
Phase 3 second trial did not meet endpoint - April 5, 2017.
Cipro DPI
Bronchiectasis
PDUFA date August 29, 2019. Company noted the date will not be met due to the postponement of an advisory committee meeting. New PDUFA date to be supplied later.
NKTR-181
Lower back pain
Phase 3 data released November 24, 2017. Endpoints not met.
Inhaled Amikacin Solution (BAY41-6551T)
Gram-Negative Pneumonia (INHALE 1)
Phase 3 topline data mid March 2015 did not reach primary endpoint.
Etirinotecan pegol NKTR-102 (BEACON)
Cancer - Metastatic Breast Cancer
Approved November 16, 2015.
ADYNOVATE
Hemophilia A
Approved September 16, 2014.
MOVANTIK (Naloxegol)
Opioid-induced constipation (OIC)
Phase 1/2 initial data March 1, 2019 noted ORR 2/11 ( 18%) - maximum tolerated dose has not been reached.
NKTR-262 and NKTR-214 - REVEAL
Solid tumors
Phase 1b data presented at EULAR June 13, 2019 - safe and well-tolerated.
NKTR-358
Systemic lupus erythematosus (SLE)
Phase 2 data presented at ASCO June 3, 2019.
NKTR-214 and nivolumab
Sarcomas
Phase 1b trial initiation announced October 7, 2019.
NKTR-358
Atopic Dermatitis
Phase 1b trial initiation announced October 7, 2019.
NKTR-358
Psoriasis

Latest News

  1. Nektar Therapeutics Announces Initiation of Two Clinical Studies of Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Psoriasis and Atopic Dermatitis

    SAN FRANCISCO, Oct. 7, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced the initiation of two Phase 1b studies of NKTR-358 (LY3471851*), a novel T regulatory (Treg) cell stimulator, one in patients

  2. Nektar Therapeutics Announces Five Abstracts Accepted for Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    SAN FRANCISCO, Oct. 2, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced the acceptance of five clinical and preclinical data abstracts for its immuno-oncology portfolio at the 2019 Society for

  3. Nektar Announces Key Executive Promotions

    SAN FRANCISCO, Oct. 1, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today several promotions on its executive leadership team:  Jonathan Zalevsky, Ph.D. has been promoted to Chief Research &

  4. Las Vegas Sands Set to Join S&P 500; Nektar Therapeutics to Join S&P MidCap 400; The Pennant Group to Join S&P SmallCap 600

    NEW YORK, Sept. 26, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600: Las Vegas Sands Corp. (NYSE:LVS) will replace Nektar

  5. Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Triple-Negative Breast Cancer Patients at the 2019 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

    SAN FRANCISCO, Sept. 26, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today a presentation of new clinical data for bempegaldesleukin (bempeg, NKTR-214) in combination with nivolumab in patients with

  6. Nektar Therapeutics Announces Abstract Accepted for Presentation at the 5th CRI-CIMT-EATI-AACR Cancer Immunotherapy Conference

    SAN FRANCISCO, Sept. 23, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that new data from a cohort of patients with metastatic triple-negative breast cancer who were enrolled in the PIVOT-02

  7. Nektar Therapeutics (NKTR), Pluralsight, Inc. (PS) & Burford Capital Limited (BRFRF, BRFRY) Class Action Update - Bronstein, Gewirtz & Grossman, LLC

    NEW YORK, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies.

  8. Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics

    The law firm of Kessler Topaz Meltzer & Check, LLP reminds that an investor securities fraud class action lawsuit has been filed against Nektar Therapeutics (NASDAQ:NKTR) ("Nektar") on behalf of those who purchased

  9. Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Nektar Therapeutics, Valaris, Burford, and Textron and Encourages Investors to Contact the Firm

    NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Nektar Therapeutics (NASDAQ:NKTR), Valaris Plc

  10. Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against Nektar Therapeutics - NKTR

    RADNOR, Pa., Sept. 3, 2019 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors that a securities fraud class action lawsuit has been filed against Nektar Therapeutics (NASDAQ:  NKTR)

  11. ROSEN, A HIGHLY RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Nektar Therapeutics – NKTR

    NEW YORK, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Nektar Therapeutics

  12. LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors to Contact the Firm

    SAN DIEGO, Aug. 30, 2019 /PRNewswire/ -- Johnson Fistel, LLP announces that class action lawsuits have been commenced on behalf of shareholders of the publicly-traded companies listed below. The Private Securities

  13. Nektar Therapeutics (NKTR), Pluralsight, Inc. (PS) & Granite Construction Incorporated (GVA) Class Actions - Bronstein, Gewirtz & Grossman, LLC

    NEW YORK, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies.

  14. ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR

    NEW YORK, Aug. 29, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Nektar Therapeutics (NASDAQ:NKTR)

  15. Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Granite Construction, Pluralsight, SAExploration, and Nektar and Encourages Investors to Contact the Firm

    NEW YORK, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Granite Construction, Inc. (NYSE:GVA),

  16. Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nektar Therapeutics

    Glancy Prongay & Murray LLP ("GPM")

  17. Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nektar Therapeutics

    Law Offices of Howard G.

  18. INVESTOR ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Plaintiff Deadline: October 18, 2019

    NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar"  or the

  19. Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)

    NEW YORK, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ:NKTR) in the United States

  20. INVESTOR ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Plaintiff Deadline: October 18, 2019

    NEW YORK, Aug. 22, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar"  or the

  21. IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigati